Stroke: Early treatment of hypertension in the acute phase
DISEASE INTERVENTION COMPARISON RESULTS
Stroke. 2003 Jul;34(7):1699-703 Randomized Controlled Trial
IN stroke, hypertension in the early acute phase The Use of
modest blood pressure reduction by angiotensin II receptor blockers, candesartan
As Treatment, Acute
Is better Than
no treatment of hypertension
To reduce cumulative 12-month mortality and reduce vascular events. No cardio-cerebrovascular event occurred as a result of hypotension
Lancet. 2011 Feb 26;377(9767):741-50 Randomized Controlled Trial, Multicenter Study
IN stroke, hypertension in the early acute phase The Use of
modest blood pressure reduction by angiotensin II receptor blockers, candesartan
As Treatment, Acute
Is worse Than
placebo
To modify death or cardiovascular events at 6 months or to modify functional outcome: higher risk of poor functional outcome with candesartan: OR 1.17.
Health Technol Assess. 2009 Jan;13(9):iii, ix-xi, 1-73 Randomized Controlled Trial
IN stroke, hypertension in the early acute phase The Use of
oral and sublingual lisinopril, oral and intravenous labetalol
As Treatment, Acute
Is better Than
placebo
To reduce mortality at 3 months, but not mortality or dependence at 2 weeks
Cochrane Database Syst Rev. 2008;(4):CD000039 Systematic Review, Cochrane Review
IN stroke, hypertension in the early acute phase The Use of
various antihypertensive treatments
As Treatment, Acute
Is equal Than
placebo
To modify mortality or functional outcome.